Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02399371 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab in Treating Patients With Malignant Mesothelioma
A Phase 2 study of Pleural Malignant Mesothelioma and Epithelioid Mesothelioma, sponsored by University of Chicago.
- Active
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
- 1
- Study location
NCT02399371 is a Phase 2 study of Pleural Malignant Mesothelioma and Epithelioid Mesothelioma that is active but no longer recruiting, run by University of Chicago. The registered enrollment target is 65 participants, above the 51-participant average among 4 other Pleural Malignant Mesothelioma trials with a reported enrollment target (27% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02399371, a Phase 2 study of Pleural Malignant Mesothelioma and Epithelioid Mesothelioma, is active but no longer recruiting, sponsored by University of Chicago.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well pembrolizumab works in treating patients with malignant mesothelioma, a cancer of the linings around the lungs (pleura) or abdomen (peritoneum). Monoclonal antibodies, such as pembrolizumab, work by blocking a protein called programmed cell death 1 (PD-1) which may stimulate an immune response and kill tumor cells.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- OTHER Laboratory Biomarker Analysis
- OTHER Pharmacogenomic Study
Study Locations (1)
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2015-03-31 |
| Est. Completion | 2026-03-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02399371
The ClinicalTrials.gov registry entry for NCT02399371 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 51-participant average among 4 other Pleural Malignant Mesothelioma trials with a reported enrollment target (27% higher). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Pleural Malignant Mesothelioma appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT02399371 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT02399371 about?
NCT02399371 is a clinical study titled "Pembrolizumab in Treating Patients With Malignant Mesothelioma". This phase II trial studies how well pembrolizumab works in treating patients with malignant mesothelioma, a cancer of the linings around the lungs (pleura) or abdomen (peritoneum). Monoclonal antibodies, such as pembrolizumab, work by blocking a protein called programmed cell death 1 (PD-1) which m...
What is the current status of trial NCT02399371?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2015-03-31. Estimated completion is 2026-03-20.
What conditions does trial NCT02399371 study?
This clinical trial studies the following conditions: Pleural Malignant Mesothelioma, Epithelioid Mesothelioma, Recurrent Peritoneal Malignant Mesothelioma, Peritoneal Malignant Mesothelioma, Pleural Biphasic Mesothelioma.
What interventions are being tested in trial NCT02399371?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Laboratory Biomarker Analysis (OTHER), Pharmacogenomic Study (OTHER).
Who is sponsoring clinical trial NCT02399371?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02399371 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pleural Malignant Mesothelioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma
COMPLETED · Phase 2
-
Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma
ACTIVE NOT RECRUITING · Phase 1
-
Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
ACTIVE NOT RECRUITING · Phase 1
-
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.